Literature DB >> 34256790

The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study.

Alina Desiree Sandø1,2, Reidun Fougner3, Jon Erik Grønbech4,5, Erling Audun Bringeland4,5.   

Abstract

BACKGROUND: Response evaluation following neoadjuvant chemotherapy (NAC) in gastric cancer is debated. The aim of this study was to investigate the value of UICC-downstaging as mode of response evaluation following a MAGIC-style regimen of NAC.
METHODS: Retrospective, population-based study on consecutive patients with resectable gastric adenocarcinoma receiving NAC from 2007 to 2016. CT-scan was obtained at diagnosis (rTNM) and repeated following NAC (yrTNM) to evaluate response in terms of downstaging. Further, yrTNM stage was crosstabulated to pathologic stage (ypTNM) to depict correlation between radiologic and pathologic assessment.
RESULTS: Of 171 patients receiving NAC, 169 were available for response evaluation. For TNM-stages, 43% responded, 50% had stable disease and 7% progressed at CT. Crosstabulating yrTNM stage to ypTNM stage, 24% had concordant stages, with CT overstaging 38% and understaging 38% of the tumours, Cohen kappa ƙ = 0,06 (95%CI 0.004-0.12). Similar patterns of discordance were found for T-stages and N-stages separately. For M-category, restaging CT detected 12 patients with carcinomatosis, with an additional 14 diagnosed with carcinomatosis only at operation. No patient developed parenchymal or extra abdominal metastases, and none developed locally non-resectable tumour during delivery of NAC. Restaging CT with response evaluation was not able to stratify patients into groups of different long-term survival rates based on response mode.
CONCLUSIONS: Routine CT-scan following NAC is of limited value. Accuracy of CT staging compared to final pathologic stage is poor, and radiologic downstaging as measure of response evaluation is unreliable and unable to discriminate long-term survival rates based on response mode.
© 2021. The Author(s).

Entities:  

Keywords:  Downstaging; Gastric cancer; Neoadjuvant chemotherapy; Response evaluation

Year:  2021        PMID: 34256790     DOI: 10.1186/s12957-021-02313-3

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  27 in total

1.  The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study.

Authors:  Mathieu Messager; Jérémie H Lefevre; Virginie Pichot-Delahaye; Amine Souadka; Guillaume Piessen; Christophe Mariette
Journal:  Ann Surg       Date:  2011-11       Impact factor: 12.969

2.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E C Smyth; M Verheij; W Allum; D Cunningham; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

Review 3.  Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer.

Authors:  K Polom; L Marano; D Marrelli; R De Luca; G Roviello; V Savelli; P Tan; F Roviello
Journal:  Br J Surg       Date:  2017-11-01       Impact factor: 6.939

4.  Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Ralf D Hofheinz; Claudia Pauligk; Hans-Georg Kopp; Georg Martin Haag; Kim Barbara Luley; Johannes Meiler; Nils Homann; Sylvie Lorenzen; Harald Schmalenberg; Stephan Probst; Michael Koenigsmann; Matthias Egger; Nicole Prasnikar; Karel Caca; Jörg Trojan; Uwe M Martens; Andreas Block; Wolfgang Fischbach; Rolf Mahlberg; Michael Clemens; Gerald Illerhaus; Katja Zirlik; Dirk M Behringer; Wolff Schmiegel; Michael Pohl; Michael Heike; Ulrich Ronellenfitsch; Martin Schuler; Wolf O Bechstein; Alfred Königsrainer; Timo Gaiser; Peter Schirmacher; Wael Hozaeel; Alexander Reichart; Thorsten O Goetze; Mark Sievert; Elke Jäger; Stefan Mönig; Andrea Tannapfel
Journal:  Lancet Oncol       Date:  2016-10-22       Impact factor: 41.316

5.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Thorsten O Goetze; Johannes Meiler; Stefan Kasper; Hans-Georg Kopp; Frank Mayer; Georg Martin Haag; Kim Luley; Udo Lindig; Wolff Schmiegel; Michael Pohl; Jan Stoehlmacher; Gunnar Folprecht; Stephan Probst; Nicole Prasnikar; Wolfgang Fischbach; Rolf Mahlberg; Jörg Trojan; Michael Koenigsmann; Uwe M Martens; Peter Thuss-Patience; Matthias Egger; Andreas Block; Volker Heinemann; Gerald Illerhaus; Markus Moehler; Michael Schenk; Frank Kullmann; Dirk M Behringer; Michael Heike; Daniel Pink; Christian Teschendorf; Carmen Löhr; Helga Bernhard; Gunter Schuch; Volker Rethwisch; Ludwig Fischer von Weikersthal; Jörg T Hartmann; Michael Kneba; Severin Daum; Karsten Schulmann; Jörg Weniger; Sebastian Belle; Timo Gaiser; Fuat S Oduncu; Martina Güntner; Wael Hozaeel; Alexander Reichart; Elke Jäger; Thomas Kraus; Stefan Mönig; Wolf O Bechstein; Martin Schuler; Harald Schmalenberg; Ralf D Hofheinz
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

6.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245

7.  Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.

Authors:  Elizabeth C Smyth; Andrew Wotherspoon; Clare Peckitt; David Gonzalez; Sanna Hulkki-Wilson; Zakaria Eltahir; Matteo Fassan; Massimo Rugge; Nicola Valeri; Alicia Okines; Madeleine Hewish; William Allum; Sally Stenning; Matthew Nankivell; Ruth Langley; David Cunningham
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 33.006

8.  Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer.

Authors:  Lin Jiang; Zhiqiang Ma; Xin Ye; Weiming Kang; Jianchun Yu
Journal:  World J Surg Oncol       Date:  2021-02-09       Impact factor: 2.754

9.  Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.

Authors:  Paula Jiménez Fonseca; Alberto Carmona-Bayonas; Raquel Hernández; Ana Custodio; Juana Maria Cano; Alejandra Lacalle; Isabel Echavarria; Ismael Macias; Monserrat Mangas; Laura Visa; Elvira Buxo; Felipe Álvarez Manceñido; Antonio Viudez; Carles Pericay; Aitor Azkarate; Avinash Ramchandani; Carlos López; Eva Martinez de Castro; Ana Fernández Montes; Federico Longo; Rodrigo Sánchez Bayona; Maria Luisa Limón; Asun Diaz-Serrano; Alfonso Martin Carnicero; David Arias; Paula Cerdà; Fernando Rivera; Jose Maria Vieitez; Manuel Sánchez Cánovas; M Garrido; J Gallego
Journal:  Br J Cancer       Date:  2017-08-01       Impact factor: 7.640

Review 10.  Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?

Authors:  Rossella Reddavid; Silvia Sofia; Paolo Chiaro; Fabio Colli; Renza Trapani; Laura Esposito; Mario Solej; Maurizio Degiuli
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

View more
  1 in total

1.  Gastric hydrodistension CT versus CT without gastric distension in preoperative TN staging of gastric carcinoma: analysis of single-center cancer registry.

Authors:  Yu-Hsien Lee; Wen-Hui Chan; Ying-Chieh Lai; An-Hsin Chen; Chien-Ming Chen
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.